Currently, MSLN-targeted therapies are investigated in many clinical trials for different solid tumor indications using different agents including CAR-T cells, monoclonal antibodies (e.g., Amatuximab, MORAb-009), drug conjugates, Immunotoxins (e.g., SS1P), T cell-engaging bispecific antibody (BiTEs) and cancer vaccines [33,34,35,36,37,38,39,40]. This evidence concerns the gene MSLN and cancer.